Over 90 Total Lots Up For Auction at One Location - WA 04/08

Atomic agency produces medical isotope for cancer treatment

Press releases may be edited for formatting or style | March 05, 2020 Molecular Imaging
The Korea Atomic Energy Research Institute (KAERI) has succeeded in producing a medical isotope that can be used for cancer diagnosis and treatment simultaneously, the state-run atomic research agency said Tuesday.

The institution said it could produce the isotope copper-67 (Cu-67), widely considered as a next-generation radioisotope for cancer treatment because it allows for the diagnosis and treatment of cancer simultaneously and has a relatively short "half-life," which means its radioactivity dissipates faster than that of other isotopes.

When Cu-67 is injected with monoclonal antibodies into a cancer patient, it helps the antibodies to destroy the cancerous tumor. KAERI said Cu-67 successfully destroyed about 80 percent of lung cancer cells in cellular experiments.
stats
DOTmed text ad

Your Centrifuge Specialty Store

Quality remanufactured Certified Centrifuges at Great prices! Fully warranted and backed by a company you can trust! Call or click for a free quote today! www.Centrifugestore.com 800-457-7576

stats
KAERI used its RFT-30 cyclotron, a device that is used for the development of medical radioisotopes and basic science research using proton beams, to produce the Cu-67. It will be supplied to local medical institutions starting the second half of 2020.

"PET scans are widely used for diagnosing cancer, but antibodies or peptides that contain Cu-67 can carry out both scanning and therapy. Cu-67 also has a relatively short half-life of 2.6 days, which means it is less dangerous, so it has been widely regarded as a next-generation radioisotope for cancer treatment," a KAERI official said.

Despite its reported superiority in treatment, producing Cu-67 takes some time due to the complexity of the procedure and high costs involved. KAERI said it had developed the technology to produce a dozen mCi (millicurie) of Cu-67; enough to supply three research institutions at the same time.

KAERI said more than 10 medical research centers here have already requested the use of Cu-67, and that it will begin supplying them from the second half of the year.

Lee Kyung-han, president of the Korean Society of Nuclear Medicine, said the production of Cu-67 will contribute to the development of the country's nuclear medicine technology.

"The successful production and supply of Cu-67 has brought the country a new chapter in theranostics ― a compound word combining therapeutics and simultaneous diagnosis," Lee said.

"The establishment of a Cu-67 production system will help the country lead the race in developing next-generation cancer treatments," Wi Myung-hwan, senior vice president of the KAERI's Advanced Radiation Technology Institute, said.


Courtesy of KAERI

Back to HCB News

You Must Be Logged In To Post A Comment